Want to see AU:RHT full AI Analyst Report?
Top Page
Resonance Health Ltd
(Sydney:RHT)
Select Model
Select Model
Rating:52Neutral
Price Target:
AU$0.07
▲(30.00% Upside)
Action:Reiterated
Date:07/30/26
The score is primarily constrained by weak financial performance—ongoing losses, negative ROE, and a large drop in free cash flow growth—despite a stable balance sheet. Technicals are a relative bright spot with the price above major moving averages, but valuation remains demanding (P/E 35) given the profitability and cash flow pressures.
Positive Factors
Recurring & usage-based revenue model
A hybrid business model of licenses/subscriptions plus per-scan fees and services supports recurring and usage-linked revenues. This mix provides durable, contractable cash inflows and aligns revenue with adoption of imaging workflows, aiding multi-month revenue predictability and customer stickiness.
Negative Factors
Negative profitability margins
Persistent negative EBIT and net income margins mean the company burns earnings at the operating level, limiting retained earnings and reinvestment capacity. Over months this constrains scaling, forces careful cost control, and raises reliance on external funding for growth or R&D programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring & usage-based revenue model
A hybrid business model of licenses/subscriptions plus per-scan fees and services supports recurring and usage-linked revenues. This mix provides durable, contractable cash inflows and aligns revenue with adoption of imaging workflows, aiding multi-month revenue predictability and customer stickiness.
Read all positive factors
Resonance Health Ltd (RHT) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$26.24M
Dividend YieldN/A
Average Volume (3M)274.25K
Price to Earnings (P/E)33.1
Beta (1Y)1.72
Revenue Growth31.36%
EPS GrowthN/A
CountryAU
Employees18
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)<0.01
Shares Outstanding477,120,240
10 Day Avg. Volume456,299
30 Day Avg. Volume274,246
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.89
Price to Sales (P/S)1.60
P/FCF Ratio22.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Resonance Health Ltd Business Overview & Revenue Model
Company Description
Resonance Health Limited is a global provider of healthcare technology and services, specializing in the design, development, and production of software-as-medical devices. The company serves markets across the Asia Pacific, Americas, Europe, Midd...
How the Company Makes Money
Resonance Health generates revenue primarily by selling access to, or use of, its medical imaging software products (including AI-enabled image analysis tools) to healthcare providers, imaging organisations, and research/pharma customers. Revenue ...
Resonance Health Ltd Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
55
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.84M | 11.07M | 8.59M | 4.40M | 3.83M | 3.78M |
| Gross Profit | 13.36M | 11.07M | 8.59M | 4.40M | 3.83M | 3.78M |
| EBITDA | 1.38M | -1.41M | -382.00K | -827.69K | -1.34M | 707.69K |
| Net Income | 769.30K | -1.73M | 169.30K | -780.00K | -1.14M | 585.86K |
Balance Sheet | ||||||
| Total Assets | 17.96M | 17.89M | 20.28M | 10.98M | 11.69M | 12.44M |
| Cash, Cash Equivalents and Short-Term Investments | 2.69M | 2.98M | 6.85M | 6.36M | 6.78M | 8.86M |
| Total Debt | 5.20M | 3.80M | 3.70M | 272.94K | 268.22K | 60.10K |
| Total Liabilities | 7.02M | 8.50M | 9.35M | 1.05M | 995.58K | 611.74K |
| Stockholders Equity | 10.94M | 9.39M | 10.93M | 9.94M | 10.69M | 11.83M |
Cash Flow | ||||||
| Free Cash Flow | 46.91K | 805.39K | 1.01M | -624.93K | -1.42M | 772.72K |
| Operating Cash Flow | 420.56K | 1.25M | 1.39M | -157.03K | -712.67K | 1.17M |
| Investing Cash Flow | -551.51K | -4.52M | -3.94M | -467.90K | -704.00K | -395.79K |
| Financing Cash Flow | -624.12K | -649.26K | 3.01M | -81.97K | -107.11K | 1.20M |
Resonance Health Ltd Technical Analysis
Neutral
0.05
Price Trends
0.05
Positive
0.05
Positive
0.05
Positive
Market Momentum
<0.01
Positive
39.58
Neutral
26.09
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:RHT, the sentiment is Neutral. The current price of 0.05 is below the 20-day moving average (MA) of 0.06, above the 50-day MA of 0.05, and above the 200-day MA of 0.05, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 39.58 is Neutral, neither overbought nor oversold. The STOCH value of 26.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:RHT.
Resonance Health Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | AU$18.98B | 81.89 | 72.67% | 0.39% | 30.33% | 138.71% | |
55 Neutral | AU$65.80M | -6.57 | -23.86% | ― | -11.45% | -97.22% | |
52 Neutral | AU$26.24M | 33.13 | 7.57% | ― | 31.36% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$33.68M | -5.50 | -14.19% | ― | 0.03% | -5.85% | |
46 Neutral | AU$61.61M | -7.91 | -59.96% | ― | ― | ― | |
43 Neutral | AU$782.23M | -28.36 | -35.63% | ― | 123.08% | 5.34% |
* Healthcare Sector Average
AU:RHT
Resonance Health Ltd
0.05
0.01
26.19%
AU:PME
Pro Medicus Limited
183.71
-128.61
-41.18%
AU:M7T
Mach7 Technologies
0.28
-0.07
-21.13%
AU:BMT
Beamtree Holdings Ltd
0.11
-0.13
-54.17%
AU:SHG
Singular Health Group Ltd
0.19
-0.14
-42.19%
AU:AYA
Artrya Limited
4.69
3.29
235.00%
Resonance Health Ltd Corporate Events
Resonance Health Director Increases Indirect Shareholding Via Off-Market Trade
Jul 15, 2026
Resonance Health Limited has reported a change in director Simon Panton’s indirect interests, with an associated entity controlled by his wife acquiring 1,640,824 ordinary fully paid shares for $73,837 in an off-market trade. Following the t...
Resonance Health Flags MRI Liver Fibrosis Progress in FY26 Portfolio Update
Jun 9, 2026
Resonance Health has published an investor presentation detailing progress on its MRI Liver Fibrosis Device and outlining its FY26 portfolio plans, alongside inviting investors to a live webinar and QA with senior management on 9 June 2026. The ev...
Resonance Health Director David Fuller Acquires Initial Indirect Shareholding
May 26, 2026
Resonance Health Limited has disclosed a change in director David Fuller’s interests, with Fuller acquiring 98,701 ordinary fully paid shares in the company via an indirect holding. The shares were purchased on market on 22 May 2026 for a to...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.